Maureen Miner, MD
Physical Medicine and Rehabilitation · Gilroy
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Office
- 1
- Since medical school
- 36 years
- Eastern Virginia Medical School, 1990
Offices
1 location
Looking this up.
Hospitals listed: Community Hospital of the Monterey Peninsula · Santa Clara Valley Medical Center. That is not proof they admit you there this week.
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Miner’s office at (408) 842-9296 to ask if they take your plan before you enroll.
California Medical Board record
Licence G73411 · Current
Licensed to practise in California · since 1992 · expires 2028-01-31 · Eastern Virginia Medical School.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
School, training and certification
What this clinician told their state board, medical school and everything before it. Only some states publish this, so nothing here means the state does not say, not that there was no training or certification.
Specialty certification
- American Board of Physical Medicine and Rehabilitation - Brain Injury Medicine
- American Board of Physical Medicine and Rehabilitation - Pain Medicine
- American Board of Physical Medicine and Rehabilitation - Physical Medicine and Rehabilitation
- American Board of Physical Medicine and Rehabilitation - Spinal Cord Injury Medicine
Hospitals they work in
2 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Community Hospital of the Monterey PeninsulaMonterey, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Montage HealthPatients rate it 4 of 5 · 84% would definitely recommend itOverall rating: 4 of 5 starsWorse than the national rate — CMS Medicare PSI 90: Patient safety and adverse events composite: 1.48 (1.22 to 1.74), Jul 2022 – Jun 2024Worse than the national rate — Postoperative acute kidney injury requiring dialysis rate: 3.12 (1.69 to 4.56) · 1,095 cases, Jul 2022 – Jun 2024Worse than the national rate — Postoperative respiratory failure rate: 19.24 (14.17 to 24.3) · 1,118 cases, Jul 2022 – Jun 2024Worse than the national rate — Postoperative sepsis rate: 9.62 (6.42 to 12.82) · 1,086 cases, Jul 2022 – Jun 2024Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.39, Oct 2024 – Sep 2025
- Santa Clara Valley Medical CenterSan Jose, CAAcute Care Hospital · Government - Local · Has an emergency department · Birthing-friendlyPart of Santa Clara Valley Health and Hospital System, which runs 3 hospitalsPatients rate it 3 of 5 · 70% would definitely recommend itOverall rating: 2 of 5 starsWorse than the national rate — SSI - Colon Surgery: 2.572, Oct 2024 – Sep 2025Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.563, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.256, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0.369, Oct 2024 – Sep 2025
See every measure and the patient survey for Community Hospital of the Monterey Peninsula
Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 1 better, 5 the same, 1 worse of 7 measures. Readmissions: 0 better, 11 the same, 0 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.48 (1.22 to 1.74) | Worse | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 3.12 (1.69 to 4.56) · 1,095 cases | Worse | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 19.24 (14.17 to 24.3) · 1,118 cases | Worse | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 9.62 (6.42 to 12.82) · 1,086 cases | Worse | Jul 2022 – Jun 2024 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.39 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.27 (0.39 to 2.16) · 1,873 cases | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 158.2 (110.65 to 205.75) · 140 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.3 · 74 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.8 · 135 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10 · 184 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9.7 · 686 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 16.4 · 1,072 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8 · 328 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.8 · 3,300 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.29 (0.11 to 0.48) · 10,234 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.1 to 0.46) · 10,572 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.25 (1.47 to 5.04) · 2,617 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.37 (1.04 to 3.7) · 2,519 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 2.21 (0.75 to 3.66) · 744 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.61 (0.06 to 1.17) · 8,715 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 5.2 · 156 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.28 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.799 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.732 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 13.7 · 152 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.6 · 625 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 6.3 · 193 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -3.2 · 749 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 7 · 1,074 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 18.5 · 850 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 4 (2.7 to 5.8) · 224 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 13.5 (10.4 to 17.4) · 224 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.7 · 153 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 11.5 · 49 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.3 · 144 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 14.2 (10.9 to 18.6) · 711 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1.2 (1 to 1.5) · 746 cases | No different | Jan 2024 – Dec 2024 |
What patients said (520 patients answered, 28% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 3 |
| Overall hospital rating | 5 |
| Quietness | 3 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 62% |
| Yes, staff "did" give patients this information | 86% |
| Yes, staff "did" give patients information about help after discharge | 84% |
| Doctors "always" explained things so they could understand | 75% |
| Doctors "always" listened carefully | 79% |
| Doctors "always" treated them with courtesy and respect | 89% |
| Patients who gave a rating of "9" or "10" (high) | 82% |
| Staff "always" explained new medications | 79% |
| Nurses "always" explained things so they could understand | 79% |
| Nurses "always" listened carefully | 77% |
| Nurses "always" treated them with courtesy and respect | 89% |
| "Always" quiet at night | 54% |
| "YES", patients would definitely recommend the hospital | 84% |
| Staff "always" explained possible side effects | 46% |
| Yes, staff "did" give patients information about possible symptoms | 88% |
See every measure and the patient survey for Santa Clara Valley Medical Center
Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 2 better, 5 the same, 1 worse of 8 measures. Readmissions: 0 better, 10 the same, 1 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| SSI - Colon SurgeryInfections | 2.572 | Worse | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.563 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.256 | Better | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.369 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.25 (0.3 to 2.2) · 1,535 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.07 (0.76 to 1.38) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 214.59 (167.38 to 261.8) · 108 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.8 · 41 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6 · 141 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10.2 · 124 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 8.3 · 501 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 14.9 · 653 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.1 · 348 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3 · 4,502 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.24 (0.04 to 0.43) · 9,014 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.34 (0.15 to 0.52) · 9,216 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 4.54 (2.51 to 6.58) · 1,421 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.54 (0 to 3.2) · 288 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.11 (0.66 to 3.56) · 1,446 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 11.61 (4.09 to 19.14) · 294 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 7.29 (3.39 to 11.2) · 299 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.9 (0.45 to 3.36) · 333 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.23 (0 to 0.78) · 7,538 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 5.4 · 94 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.735 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 2.573 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.6 · 185 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 22.1 · 951 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 56.3 · 128 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 6.4 · 644 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 1.3 · 699 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.3 · 921 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.7 (3.9 to 8.1) · 226 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 12.6 (9.4 to 16.5) · 226 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.4 · 94 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 11.4 · 54 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.3 · 242 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.2 (9.9 to 17.4) · 702 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.7 to 1.4) · 195 cases | No different | Jan 2024 – Dec 2024 |
What patients said (4,032 patients answered, 29% of those asked)
| Cleanliness | 3 |
| Nurse communication | 3 |
| Doctor communication | 3 |
| Communication about medicines | 3 |
| Discharge information | 2 |
| Overall hospital rating | 3 |
| Quietness | 2 |
| Recommend hospital | 4 |
| Room was "always" clean | 70% |
| Nurses "always" communicated well | 73% |
| Doctors "always" communicated well | 76% |
| Staff "always" explained | 57% |
| Yes, staff "did" give patients this information | 82% |
| Yes, staff "did" give patients information about help after discharge | 82% |
| Doctors "always" explained things so they could understand | 71% |
| Doctors "always" listened carefully | 74% |
| Doctors "always" treated them with courtesy and respect | 82% |
| Patients who gave a rating of "9" or "10" (high) | 67% |
| Staff "always" explained new medications | 71% |
| Nurses "always" explained things so they could understand | 71% |
| Nurses "always" listened carefully | 69% |
| Nurses "always" treated them with courtesy and respect | 80% |
| "Always" quiet at night | 43% |
| "YES", patients would definitely recommend the hospital | 70% |
| Staff "always" explained possible side effects | 44% |
| Yes, staff "did" give patients information about possible symptoms | 83% |
Original Medicare doctor bills
$16,403
Medicare paid this office $16,403 for 28 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Short return visit | 17 | $5,870 | $48 |
| Long return visit (40+ min) | 21 | $5,236 | $145 |
| Return visit (30+ min) | 16 | $2,149 | $107 |
| Testing for presence of drug, read by direct observation | 17 | $914 | $12 |
Who their Medicare patients are
28 Original Medicare patients in 2024. Average age 69 · Women 54% · Health risk score 2.59. Sicker patients than 9 in 10 peers; the typical physical medicine and rehabilitation clinician is at 1.53.
Conditions among them: High blood pressure 68% · Depression 39%.
The office billed $46,694, Medicare allowed $22,615 and paid $16,403; for 277 services of 11 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 28 | 277 | 69 | 2.59 | $46,694 | $16,403 |
| 2023 | 24 | 286 | 68 | 1.98 | $45,526 | $16,208 |
| 2022 | 22 | 288 | 68 | 3.01 | $45,290 | $16,436 |
| 2021 | 33 | 250 | 70 | 1.60 | $32,463 | $16,563 |
| 2020 | 37 | 327 | 70 | 1.69 | $48,734 | $20,772 |
| 2019 | 39 | 275 | 70 | 1.87 | $44,785 | $18,225 |
| 2018 | 41 | 323 | 68 | 1.99 | $50,479 | $21,154 |
| 2017 | 31 | 236 | 68 | 2.42 | $36,614 | $14,838 |
| 2016 | 32 | 438 | 69 | 2.06 | $40,217 | $16,346 |
| 2015 | 36 | 579 | 69 | 2.11 | $44,061 | $17,954 |
| 2014 | 47 | 604 | 67 | 1.57 | $56,100 | $22,833 |
| 2013 | 45 | 563 | 67 | 1.71 | $58,475 | $23,779 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 5 services
| Short return visit | 15 | $5,764 | $48 |
| Long return visit (40+ min) | 18 | $5,473 | $152 |
| Return visit (30+ min) | 11 | $1,627 | $102 |
| Testing for presence of drug, read by direct observation | 13 | $1,025 | $12 |
| Short return visit (20+ min) | 11 | $936 | $78 |
2022: 4 services
| Short return visit | 11 | $6,131 | $49 |
| Long return visit (40+ min) | 21 | $5,384 | $158 |
| Return visit (30+ min) | 13 | $1,875 | $117 |
| Testing for presence of drug, read by direct observation | 14 | $907 | $12 |
2021: 6 services
| Short return visit | 17 | $6,109 | $54 |
| Return visit (30+ min) | 23 | $4,041 | $112 |
| Long return visit (40+ min) | 13 | $2,885 | $160 |
| Short return visit (20+ min) | 11 | $950 | $68 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 17 | $368 | $11 |
| Testing for presence of drug, read by direct observation | 12 | $214 | $13 |
2020: 5 services
| Return visit (30+ min) | 29 | $5,467 | $94 |
| Long return visit (40+ min) | 21 | $4,554 | $117 |
| Short return visit (20+ min) | 20 | $2,873 | $68 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 20 | $2,749 | $21 |
| Short return visit | 12 | $568 | $35 |
2019: 4 services
| Long return visit (40+ min) | 23 | $5,878 | $122 |
| Return visit (30+ min) | 28 | $5,212 | $93 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 13 | $2,100 | $21 |
| Short return visit (20+ min) | 16 | $1,538 | $64 |
2018: 5 services
| Return visit (30+ min) | 28 | $6,131 | $97 |
| Long return visit (40+ min) | 20 | $4,361 | $125 |
| Short return visit (20+ min) | 18 | $2,357 | $67 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 16 | $2,143 | $20 |
| Testing for presence of drug, read by direct observation | 12 | $237 | $13 |
2017: 4 services
| Long return visit (40+ min) | 16 | $4,601 | $124 |
| Return visit (30+ min) | 18 | $2,759 | $92 |
| Short return visit (20+ min) | 15 | $1,794 | $64 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 12 | $1,465 | $18 |
2016: 4 services
| Long return visit (40+ min) | 20 | $4,256 | $118 |
| Return visit (30+ min) | 19 | $3,536 | $96 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 11 | $1,344 | $17 |
| Drug tests(s), presumptive, any number of drug classes; any number of devices or procedures, (eg immunoassay) capable of being read by direct optical observation only (eg, dipsticks, cups, cards, cartridges), includes sample validation when performed, per | 13 | $291 | $15 |
2015: 4 services
| Long return visit (40+ min) | 20 | $4,670 | $130 |
| Return visit (30+ min) | 23 | $3,502 | $92 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 14 | $2,204 | $17 |
| Short return visit (20+ min) | 11 | $1,283 | $64 |
2014: 5 services
| Return visit (30+ min) | 35 | $6,327 | $92 |
| Long return visit (40+ min) | 18 | $3,485 | $129 |
| Short return visit (20+ min) | 32 | $3,139 | $64 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 19 | $2,661 | $19 |
| Drug screen, other than chromatographic; any number of drug classes, by clia waived test or moderate complexity test, per patient encounter | 19 | $544 | $19 |
2013: 4 services
| Return visit (30+ min) | 28 | $6,889 | $91 |
| Long return visit (40+ min) | 17 | $3,125 | $116 |
| Short return visit (20+ min) | 21 | $2,472 | $60 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 19 | $2,305 | $18 |
Drugs they prescribed that Part D paid
$43,927
Pharmacies billed $43,927 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 20% of their Part D prescriptions (136 of 679) in 2024. Above the middle of the specialty; the typical physical medicine and rehabilitation clinician is at 12%. Long-acting opioids: 34% of their opioid prescriptions.
606 generic and 73 brand-name prescriptions · $43,927 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Oxycontin | 24 | $15,462 | $644 |
| Eliquis | 12 | $7,994 | $666 |
| Hydrocodone-Acetaminophen | 38 | $2,372 | $62 |
| Eszopiclone | 37 | $2,360 | $64 |
| Olanzapine | 11 | $2,010 | $183 |
See all 24 drugs
| Oxycontin | 24 | $15,462 | $644 |
| Eliquis | 12 | $7,994 | $666 |
| Hydrocodone-Acetaminophen | 38 | $2,372 | $62 |
| Eszopiclone | 37 | $2,360 | $64 |
| Olanzapine | 11 | $2,010 | $183 |
| Fentanyl | 22 | $1,198 | $54 |
| Baclofen | 39 | $907 | $23 |
| Gabapentin | 43 | $610 | $14 |
| Donepezil | 44 | $467 | $11 |
| Zolpidem Tartrate Er | 13 | $458 | $35 |
| Oxycodone | 39 | $430 | $11 |
| Armodafinil | 11 | $325 | $30 |
| Pregabalin | 11 | $260 | $24 |
| Hydroxyzine | 12 | $234 | $20 |
| Sertraline | 19 | $218 | $11 |
| Levothyroxine | 16 | $213 | $13 |
| Celecoxib | 18 | $194 | $11 |
| Duloxetine | 26 | $140 | $5 |
| Topiramate | 16 | $116 | $7 |
| Cyclobenzaprine | 15 | $104 | $7 |
| Trazodone | 11 | $101 | $9 |
| Ibuprofen | 14 | $70 | $5 |
| Memantine | 13 | $57 | $4 |
| Diazepam | 16 | $23 | $1 |
Year by year
| 2024 | 679 | 40 | 20% (136) | 11% | $43,927 |
| 2023 | 609 | 38 | 18% (110) | 9% | $53,668 |
| 2022 | 657 | 43 | 19% (127) | 7% | $37,962 |
| 2021 | 858 | 54 | 22% (185) | 5% | $49,417 |
| 2020 | 1,098 | 54 | 20% (222) | 6% | $58,852 |
| 2019 | 1,075 | 45 | 21% (230) | 8% | $68,656 |
| 2018 | 967 | 46 | 25% (245) | 7% | $61,190 |
| 2017 | 931 | 43 | 28% (261) | 9% | $53,854 |
| 2016 | 829 | 42 | 27% (227) | 17% | $61,917 |
| 2015 | 679 | 38 | 31% (213) | 23% | $66,664 |
| 2014 | 857 | 42 | 36% (311) | 18% | $64,383 |
| 2013 | 743 | 36 | 43% (322) | 18% | $55,231 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 17 drugs
| Oxycontin | 13 | $15,866 | $1,220 |
| Eliquis | 21 | $12,585 | $599 |
| Pregabalin | 25 | $3,425 | $137 |
| Armodafinil | 12 | $2,189 | $182 |
| Eszopiclone | 46 | $2,088 | $45 |
| Fentanyl | 23 | $1,589 | $69 |
| Hydrocodone-Acetaminophen | 29 | $1,262 | $44 |
| Donepezil | 34 | $1,099 | $32 |
| Duloxetine | 24 | $987 | $41 |
| Baclofen | 30 | $717 | $24 |
| Gabapentin | 21 | $534 | $25 |
| Oxycodone | 35 | $474 | $14 |
| Celecoxib | 14 | $364 | $26 |
| Trazodone | 25 | $218 | $9 |
| Famotidine | 13 | $180 | $14 |
| Ibuprofen | 13 | $134 | $10 |
| Topiramate | 13 | $100 | $8 |
2022: 20 drugs
| Armodafinil | 13 | $1,714 | $132 |
| Hydrocodone-Acetaminophen | 38 | $1,612 | $42 |
| Eszopiclone | 38 | $1,524 | $40 |
| Pregabalin | 30 | $1,395 | $47 |
| Gabapentin | 39 | $1,067 | $27 |
| Celecoxib | 25 | $1,019 | $41 |
| Fentanyl | 22 | $873 | $40 |
| Midodrine | 11 | $807 | $73 |
| Baclofen | 29 | $729 | $25 |
| Duloxetine | 24 | $677 | $28 |
| Oxycodone | 41 | $625 | $15 |
| Venlafaxine Hcl Er | 13 | $376 | $29 |
| Donepezil | 26 | $348 | $13 |
| Nortriptyline | 13 | $180 | $14 |
| Famotidine | 12 | $156 | $13 |
| Risperidone | 12 | $147 | $12 |
| Topiramate | 13 | $107 | $8 |
| Trazodone | 23 | $66 | $3 |
| Sertraline | 11 | $65 | $6 |
| Buspirone | 11 | $62 | $6 |
2021: 27 drugs
| Oxycontin | 13 | $14,392 | $1,107 |
| Eliquis | 12 | $6,327 | $527 |
| Tiagabine | 11 | $5,768 | $524 |
| Pregabalin | 41 | $2,254 | $55 |
| Baclofen | 42 | $2,235 | $53 |
| Hydrocodone-Acetaminophen | 44 | $1,682 | $38 |
| Oxycodone | 65 | $1,356 | $21 |
| Eszopiclone | 42 | $1,349 | $32 |
| Gabapentin | 63 | $1,288 | $20 |
| Fentanyl | 21 | $1,088 | $52 |
| Methenamine Hippurate | 12 | $933 | $78 |
| Armodafinil | 11 | $683 | $62 |
| Midodrine | 21 | $561 | $27 |
| Venlafaxine Hcl Er | 19 | $526 | $28 |
| Oxycodone-Acetaminophen | 17 | $525 | $31 |
| Risperidone | 20 | $455 | $23 |
| Celecoxib | 28 | $406 | $14 |
| Trazodone | 48 | $364 | $8 |
| Sertraline | 20 | $358 | $18 |
| Nitrofurantoin Mono-Macro | 11 | $234 | $21 |
| Naproxen | 11 | $221 | $20 |
| Duloxetine | 21 | $171 | $8 |
| Cyclobenzaprine | 20 | $95 | $5 |
| Escitalopram | 12 | $93 | $8 |
| Topiramate | 11 | $85 | $8 |
| Donepezil | 11 | $38 | $3 |
| Meloxicam | 13 | $19 | $1 |
2020: 32 drugs
| Oxycontin | 13 | $13,862 | $1,066 |
| Eliquis | 13 | $6,338 | $488 |
| Pregabalin | 45 | $2,664 | $59 |
| Baclofen | 50 | $2,069 | $41 |
| Oxycodone | 67 | $1,684 | $25 |
| Hydrocodone-Acetaminophen | 47 | $1,393 | $30 |
| Gabapentin | 103 | $1,391 | $14 |
| Fentanyl | 19 | $1,255 | $66 |
| Eszopiclone | 38 | $1,210 | $32 |
| Armodafinil | 12 | $1,047 | $87 |
| Venlafaxine Hcl Er | 31 | $894 | $29 |
| Celecoxib | 43 | $698 | $16 |
| Morphine Sulfate Er | 17 | $546 | $32 |
| Topiramate | 11 | $510 | $46 |
| Tramadol Hcl-Acetaminophen | 13 | $506 | $39 |
| Oxycodone-Acetaminophen | 16 | $448 | $28 |
| Ziprasidone | 20 | $438 | $22 |
| Trazodone | 55 | $314 | $6 |
| Divalproex | 13 | $310 | $24 |
| Buspirone | 26 | $308 | $12 |
| Duloxetine | 21 | $284 | $14 |
| Risperidone | 12 | $271 | $23 |
| Clonazepam | 19 | $200 | $11 |
| Sertraline | 21 | $185 | $9 |
| Tramadol | 16 | $176 | $11 |
| Cyclobenzaprine | 21 | $145 | $7 |
| Chlorhexidine Gluconate | 16 | $141 | $9 |
| Propranolol | 22 | $99 | $5 |
| Lorazepam | 13 | $87 | $7 |
| Meloxicam | 18 | $70 | $4 |
| Diazepam | 18 | $70 | $4 |
| Morphine Sulfate | 12 | $57 | $5 |
2019: 40 drugs
| Oxycontin | 12 | $15,906 | $1,326 |
| Lyrica | 15 | $12,538 | $836 |
| Eliquis | 12 | $5,391 | $449 |
| Fentanyl | 38 | $3,701 | $97 |
| Baclofen | 69 | $3,421 | $50 |
| Oxycodone | 78 | $1,746 | $22 |
| Gabapentin | 75 | $1,049 | $14 |
| Oxybutynin Chloride | 16 | $923 | $58 |
| Armodafinil | 12 | $889 | $74 |
| Buspirone | 29 | $812 | $28 |
| Venlafaxine Hcl Er | 30 | $738 | $25 |
| Eszopiclone | 31 | $721 | $23 |
| Ziprasidone | 23 | $605 | $26 |
| Tramadol | 22 | $603 | $27 |
| Trazodone | 47 | $513 | $11 |
| Ibuprofen | 24 | $504 | $21 |
| Amitriptyline | 11 | $469 | $43 |
| Tramadol Hcl-Acetaminophen | 14 | $464 | $33 |
| Hydrocodone-Acetaminophen | 28 | $439 | $16 |
| Constulose | 21 | $400 | $19 |
| Divalproex | 13 | $384 | $30 |
| Duloxetine | 19 | $338 | $18 |
| Sertraline | 29 | $314 | $11 |
| Celecoxib | 32 | $304 | $10 |
| Tizanidine | 11 | $264 | $24 |
| Oxycodone-Acetaminophen | 11 | $249 | $23 |
| Valproic Acid | 12 | $205 | $17 |
| Topiramate | 11 | $202 | $18 |
| Cyclobenzaprine | 18 | $161 | $9 |
| Lorazepam | 23 | $147 | $6 |
| Chlorhexidine Gluconate | 17 | $137 | $8 |
| Propranolol | 24 | $133 | $6 |
| Hydromorphone | 18 | $125 | $7 |
| Donepezil | 12 | $123 | $10 |
| Clonazepam | 19 | $111 | $6 |
| Levetiracetam | 12 | $102 | $9 |
| Omeprazole | 12 | $101 | $8 |
| Meloxicam | 15 | $101 | $7 |
| Naproxen | 11 | $99 | $9 |
| Diazepam | 11 | $35 | $3 |
2018: 35 drugs
| Oxycontin | 13 | $15,323 | $1,179 |
| Armodafinil | 11 | $4,347 | $395 |
| Fentanyl | 50 | $3,850 | $77 |
| Movantik | 11 | $3,842 | $349 |
| Baclofen | 58 | $2,245 | $39 |
| Oxycodone | 77 | $1,526 | $20 |
| Gabapentin | 65 | $985 | $15 |
| Oxybutynin Chloride | 22 | $780 | $35 |
| Duloxetine | 26 | $773 | $30 |
| Hydrocodone-Acetaminophen | 32 | $732 | $23 |
| Oxycodone-Acetaminophen | 22 | $727 | $33 |
| Eszopiclone | 18 | $674 | $37 |
| Ziprasidone | 12 | $609 | $51 |
| Amitriptyline | 14 | $573 | $41 |
| Midodrine | 15 | $543 | $36 |
| Trazodone | 54 | $439 | $8 |
| Tramadol | 19 | $416 | $22 |
| Divalproex | 12 | $344 | $29 |
| Ibuprofen | 18 | $338 | $19 |
| Sertraline | 28 | $299 | $11 |
| Venlafaxine Hcl Er | 17 | $240 | $14 |
| Celecoxib | 17 | $240 | $14 |
| Buspirone | 30 | $235 | $8 |
| Hydromorphone | 30 | $221 | $7 |
| Propranolol | 24 | $206 | $9 |
| Donepezil | 13 | $200 | $15 |
| Chlorhexidine Gluconate | 19 | $166 | $9 |
| Valproic Acid | 12 | $162 | $13 |
| Clonazepam | 17 | $135 | $8 |
| Lorazepam | 17 | $131 | $8 |
| Polyethylene Glycol 3350 | 16 | $121 | $8 |
| Naproxen | 12 | $108 | $9 |
| Levetiracetam | 12 | $106 | $9 |
| Omeprazole | 12 | $102 | $8 |
| Meloxicam | 13 | $34 | $3 |
2017: 34 drugs
| Oxycontin | 19 | $13,266 | $698 |
| Armodafinil | 13 | $3,716 | $286 |
| Fentanyl | 43 | $3,368 | $78 |
| Amitiza | 15 | $2,821 | $188 |
| Gabapentin | 77 | $1,882 | $24 |
| Oxycodone | 69 | $1,418 | $21 |
| Morphine Sulfate Er | 23 | $1,114 | $48 |
| Oxybutynin Chloride | 39 | $1,084 | $28 |
| Oxycodone-Acetaminophen | 26 | $1,075 | $41 |
| Baclofen | 38 | $998 | $26 |
| Tizanidine | 17 | $850 | $50 |
| Divalproex | 12 | $663 | $55 |
| Hydrocodone-Acetaminophen | 34 | $591 | $17 |
| Ziprasidone | 12 | $577 | $48 |
| Celecoxib | 20 | $337 | $17 |
| Sertraline | 31 | $318 | $10 |
| Tramadol | 15 | $285 | $19 |
| Trazodone | 41 | $270 | $7 |
| Duloxetine | 11 | $242 | $22 |
| Levothyroxine | 13 | $235 | $18 |
| Buspirone | 28 | $235 | $8 |
| Ibuprofen | 12 | $227 | $19 |
| Hydromorphone | 27 | $220 | $8 |
| Donepezil | 22 | $211 | $10 |
| Hydroxyzine | 14 | $170 | $12 |
| Propranolol | 16 | $169 | $11 |
| Levetiracetam | 16 | $157 | $10 |
| Venlafaxine Hcl Er | 12 | $146 | $12 |
| Valproic Acid | 11 | $143 | $13 |
| Omeprazole | 13 | $122 | $9 |
| Naproxen | 13 | $115 | $9 |
| Lorazepam | 15 | $108 | $7 |
| Meloxicam | 14 | $93 | $7 |
| Clonazepam | 16 | $63 | $4 |
2016: 29 drugs
| Lyrica | 25 | $12,697 | $508 |
| Oxycontin | 16 | $10,110 | $632 |
| Amitiza | 18 | $3,781 | $210 |
| Fentanyl | 29 | $2,434 | $84 |
| Aripiprazole | 12 | $2,393 | $199 |
| Celecoxib | 21 | $1,815 | $86 |
| Gabapentin | 68 | $1,528 | $22 |
| Morphine Sulfate Er | 23 | $1,402 | $61 |
| Baclofen | 45 | $1,241 | $28 |
| Hydrocodone-Acetaminophen | 42 | $1,098 | $26 |
| Oxycodone | 52 | $1,033 | $20 |
| Oxycodone-Acetaminophen | 17 | $834 | $49 |
| Oxybutynin Chloride | 14 | $814 | $58 |
| Duloxetine | 11 | $802 | $73 |
| Ziprasidone | 12 | $670 | $56 |
| Levothyroxine | 22 | $379 | $17 |
| Lamotrigine | 19 | $347 | $18 |
| Trazodone | 33 | $249 | $8 |
| Sertraline | 26 | $196 | $8 |
| Hydromorphone | 24 | $184 | $8 |
| Olanzapine | 11 | $180 | $16 |
| Tramadol | 17 | $172 | $10 |
| Ibuprofen | 11 | $157 | $14 |
| Buspirone | 17 | $148 | $9 |
| Omeprazole | 12 | $121 | $10 |
| Valproic Acid | 11 | $96 | $9 |
| Lorazepam | 14 | $94 | $7 |
| Propranolol | 12 | $86 | $7 |
| Clonazepam | 15 | $40 | $3 |
2015: 26 drugs
| Oxycontin | 24 | $14,979 | $624 |
| Lyrica | 36 | $11,489 | $319 |
| Nuvigil | 11 | $6,144 | $559 |
| Vesicare | 14 | $4,486 | $320 |
| Morphine Sulfate Er | 37 | $2,246 | $61 |
| Fentanyl | 17 | $1,851 | $109 |
| Baclofen | 52 | $1,465 | $28 |
| Oxycodone | 45 | $1,250 | $28 |
| Hydrocodone-Acetaminophen | 33 | $1,204 | $36 |
| Ziprasidone | 12 | $1,159 | $97 |
| Gabapentin | 43 | $1,121 | $26 |
| Oxycodone-Acetaminophen | 13 | $1,068 | $82 |
| Oxybutynin Chloride Er | 11 | $1,008 | $92 |
| Oxybutynin Chloride | 13 | $825 | $63 |
| Duloxetine | 13 | $754 | $58 |
| Levothyroxine | 15 | $274 | $18 |
| Sertraline | 24 | $180 | $8 |
| Omeprazole | 12 | $131 | $11 |
| Buspirone | 12 | $121 | $10 |
| Trazodone | 17 | $118 | $7 |
| Hydromorphone | 24 | $99 | $4 |
| Valproic Acid | 11 | $92 | $8 |
| Lorazepam | 12 | $92 | $8 |
| Tramadol | 12 | $87 | $7 |
| Tizanidine | 12 | $83 | $7 |
| Propranolol | 12 | $80 | $7 |
2014: 30 drugs
| Oxycontin | 37 | $15,106 | $408 |
| Lyrica | 28 | $7,478 | $267 |
| Fentanyl | 40 | $6,722 | $168 |
| Duloxetine | 20 | $3,146 | $157 |
| Vesicare | 13 | $2,856 | $220 |
| Lidocaine | 33 | $2,629 | $80 |
| Ziprasidone | 16 | $2,037 | $127 |
| Morphine Sulfate Er | 36 | $1,824 | $51 |
| Levorphanol | 11 | $1,694 | $154 |
| Oxycodone | 52 | $1,435 | $28 |
| Hydrocodone-Acetaminophen | 49 | $1,346 | $27 |
| Oxybutynin Chloride | 28 | $1,155 | $41 |
| Gabapentin | 46 | $1,021 | $22 |
| Oxycodone-Acetaminophen | 13 | $824 | $63 |
| Voltaren | 13 | $708 | $54 |
| Baclofen | 32 | $522 | $16 |
| Econazole Nitrate | 12 | $515 | $43 |
| Enalapril Maleate | 15 | $248 | $17 |
| Tramadol | 24 | $233 | $10 |
| Levothyroxine | 15 | $226 | $15 |
| Omeprazole | 12 | $213 | $18 |
| Hydromorphone | 24 | $204 | $9 |
| Sertraline | 12 | $201 | $17 |
| Temazepam | 13 | $130 | $10 |
| Buspirone | 12 | $124 | $10 |
| Valproic Acid | 12 | $117 | $10 |
| Methadone | 17 | $115 | $7 |
| Trazodone | 16 | $112 | $7 |
| Lorazepam | 12 | $95 | $8 |
| Propranolol | 12 | $60 | $5 |
2013: 25 drugs
| Oxycontin | 22 | $11,959 | $544 |
| Fentanyl | 42 | $7,404 | $176 |
| Lyrica | 14 | $4,327 | $309 |
| Cymbalta | 20 | $4,300 | $215 |
| Vesicare | 12 | $2,425 | $202 |
| Avinza | 13 | $2,159 | $166 |
| Ziprasidone | 12 | $1,903 | $159 |
| Gabapentin | 51 | $1,863 | $37 |
| Oxycodone | 75 | $1,812 | $24 |
| Morphine Sulfate Er | 38 | $1,039 | $27 |
| Hydrocodone-Acetaminophen | 44 | $991 | $23 |
| Oxybutynin Chloride | 20 | $532 | $27 |
| Tramadol | 29 | $314 | $11 |
| Omeprazole | 12 | $282 | $23 |
| Levothyroxine | 21 | $233 | $11 |
| Sertraline | 12 | $220 | $18 |
| Baclofen | 17 | $199 | $12 |
| Valproic Acid | 12 | $173 | $14 |
| Hydromorphone | 14 | $168 | $12 |
| Trazodone | 18 | $139 | $8 |
| Temazepam | 13 | $129 | $10 |
| Methadone | 19 | $125 | $7 |
| Buspirone | 12 | $117 | $10 |
| Lorazepam | 12 | $112 | $9 |
| Propranolol | 12 | $60 | $5 |
Money from drug and device companies
$19 in 2022
A payment is not proof that care is biased.
| Allergan | Botox | $19 | 1 payment
|
See the published payment
| Allergan | Meals · 2022-02-07 | Botox | $19 |
Professional record
- NPI
- 1992746960
- Licence
- CA G73411California G73411: Current · expires 2028-01-31
- Trained
- Eastern Virginia Medical School, 1990 · 36 years ago
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 225400000X (225400000X)
- Mailing address
- Po Box 1812, Morgan Hill, CA, 95038
- NPI first listed
- 2006-06-09
- NPI last updated
- 2023-08-17
- NPI record certified
- 2023-08-17
This is when the NPI record was last certified, not a medical board exam.